Full Press Release Details
Life Sciences Announces Resignation of CEO
York, July 15, 2022 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"),
a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that the Board of Directors
has accepted the voluntary resignation of Dr. Kunwar Shailubhai as Chief Executive Officer, Chief Scientific Officer and Board director,
effective as of August 1, 2022. Dr. Shailubhai resigned for personal reasons, and
his resignation is not related to any disagreement with the Company on any matter relating to the Company's operations, policies
Board has appointed Gabriele Cerrone, Executive Chairman of Tiziana, as interim Chief Executive Officer to lead the Company through this
period of transition. The Board will begin a search for a permanent Chief Executive Officer and Chief Scientific Officer immediately.
behalf of the Board, I want to thank Kunwar for his many years of exceptional service to Tiziana and his commitment to our vision in
providing locally acting antibody therapies to patients with unmet needs," said Gabriele Cerrone, Executive Chairman of Tiziana.
"We wish Kunwar well in his future endeavors. We continue to advance our foralumab clinical development programs as planned, and
will provide a progress update in due course," he added.
Tiziana Life Sciences
Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies
to enable alternative routes of immunotherapy. Tiziana's innovative nasal, oral and inhalation approaches in development have the
potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana's
two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated
a favorable safety profile and clinical response in patients in studies to date. Tiziana's technology for alternative routes of
immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
| Tiziana Life Sciences Ltd Hana Malik, Business Development, and Investor Relations Manager +44 (0) 207 495 2379 email: info@tizianalifesciences.com | |
| Investors: Irina Koffler LifeSci Advisors, LLC 646.970.4681 ikoffler@lifesciadvisors.com |